Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate

Radiotherapy and Oncology

Volumn 40, Issue 2, 1996, Pages 159-162

  Zietman, A L ^a   Tibbs, M K ^a   Dallow, K C ^a   Smith, C T ^a   Althausen, A F ^a   Zlotecki, R A ^a   Shipley, W U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Prostate cancer; PSA nadir; Radiation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

EID: 0030220295     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-8140(96)01770-7     Document Type: Article

References (16)

1. [1] Blasko, J.C., Grimm, P.D. and Ragde, H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Sem. Radiat. Oncol. 3: 240-249, 1993.
2. [2] Corn, B.W., Hanks, G.E., Schultheiss, T.E., Hunt, M.A., Lee, W.R. and Coia, L.R. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int. J. Radiat. Oncol. Biol. Phys. 32: 325-330, 1995.
3. [3] Cox, D.R and Oakes, D. Analysis of Survival Data. Chapman and Hall, London, 1984.
4. [4] Critz, F.A., Tarlton, R.S. and Holladay, D.A. Prostate-specific antigen monitored combination radiotherapy for patients with prostate cancer. Cancer 75: 2383-2391, 1995.
5. [5] Crook, J., Perry, G., Robertson, S. and Esche, B. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Proc. Am. Urol. Assoc. J. Urol. 153: Abstract 1095, 1995.
6. [6] Dugan, T.C., Verhey, L.J. and Shipley, W.U. Post-irradiation biopsy of the prostate in stage T3 prostatic cancer: correlation with original histologic grade and with current PSA values. Int. J. Radiat. Oncol. Biol. Phys. 19: 198-199, 1990.
7. [7] Hanks, G.E., Perez, C.A., Kozar, M.B., Asbell, S.O., Pilepich, M. V. and Kaplan, R. PSA confirmation of cure at 10 years for T1b-T2 N0 M0 prostate cancer patients treated in RTOG protocol 7706 with external radiation. Int. J. Radiat. Oncol. Biol. Phys 30: 289-292, 1994.
8. [8] Kaplan, E.L. and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53: 457, 1958
9. [9] Kaplan, I.D., Cox, R.S. and Bagshaw, M.A. Radiotherapy for prostate cancer: patient selection and the impact of local control. Urology 43: 634-639, 1994.
10. [10] Lange, P.H., Ercole, C.J., Lightner, D.J., Fraley, E.E. and Vessella, R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141: 873-879, 1989.
11. [11] Laramore, G.E., Krall, J.M., Thomas, F.J., Russell, K.J., Maor, M.H., Hendrickson, F.R., Martz, K.L., Griffin, T.W. and Davis, L.W. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of the Radiation Therapy Oncology Group randomized clinical trial. Am. J. Clin. Oncol. 16: 164-167, 1993.
12. [12] Russell, K.J. and Boileau, M.A. Current status of prostate-specific antigen in the radiotherapeutic management of prostate cancer. Sem. Radiat. Oncol. 3: 154-168, 1993.
13. [13] Willett, C.G., Zietman, A.L., Shipley, W.U. and Coen, J.J. The effect of pelvic radiation therapy on the production of prostatic specific antigen. J. Urol. 151: 1579-1581, 1994.
14. [14] Zagars, G.K., Pollack, A., Kavadi, V.S. and von Eschenbach, A.C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32: 293-306, 1995.
15. [15] Zelefsky, M.J., Leibel, S.A., Wallner, K.E., Whitmore, W.F. and Fuks, Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J. Clin. Oncol. 13: 459-463, 1995.
16. [16] Zietman, A.L., Coen, J.J., Shipley, W.U. and Efird, J. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial PSA value as a predictor of treatment outcome. J. Urol. 151: 640-645, 1994.